Mutlu Arat

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 636 citations

Medicine, Hematology, Pharmacotherapy +15

Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation

Mohamad Mohty, Florent Malard, Michaël Abécassis et al. · Bone Marrow Transplantation · 2016 · 529 citations · Full text

Medicine, Hematology, Early Detection +12

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Philippe Moreau, Meletios Α. Dimopoulos, Joseph Mıkhael et al. · The Lancet · 2021 · 380 citations

Medicine, Pharmacology, Pharmacotherapy +12

NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet α-granules

Meral Gunay‐Aygun, Tzipora C. Falik‐Zaccai, Thierry Vilboux et al. · Nature Genetics · 2011 · 259 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +12

Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation

Olaf Penack, Monia Marchetti, Mahmoud Aljurf et al. · The Lancet Haematology · 2024 · 222 citations · Full text

Medicine, Hematology, Immunology +17